Compared to “pure” DLB, DLB/AD+ patients have shown a more severe disease manifestation (Howlett et al., 2015; Lemstra et al., 2017) and a synergistic effect of α-synuclein and amyloid and tau pathology is suspected (Howlett et al., 2015). The gene discussed is MAPT; the disease is Alzheimer disease.